Cannabinoid Therapy for Chronic Pain: Weighing Mixed Evidence Against a Real Interaction
A man already using cannabis on his own for chronic nerve pain wants his pain clinic to formally endorse and monitor it, and the honest answer sits between real, if modest, evidence of benefit and a genuine interaction risk with a drug he can't safely destabilize.
A.B., a 61-year-old man, has lived with painful diabetic peripheral neuropathy in both feet for nearly eight years, a complication of type 2 diabetes he manages along with atrial fibrillation, for which he takes warfarin — his cardiologist switched him from a newer anticoagulant two years ago after his insurance stopped covering it, and he has stayed on warfarin since, with an INR that has run stable and in range at every check. He retired last year from running a small hardware store, and describes the neuropathic burning in his feet as the thing that actually shaped his retirement timeline more than his age did — standing on a concrete floor all day had become close to unbearable. Gabapentin helps some, duloxetine helps a little more, but six months ago, at a neighbor's suggestion, he started using an over-the-counter THC/CBD tincture most evenings and reports it has done more for his pain than either prescribed medication alone. He brought the bottle to this visit and asked, directly, whether his pain clinic would formally support and monitor what he's already doing.
The evidence base he's pointing to is real: the National Academies of Sciences' comprehensive 2017 review found substantial evidence that cannabis and cannabinoids are effective for chronic pain in adults, a conclusion later chronic-pain-specific meta-analyses have generally supported while also finding the actual effect sizes modest rather than dramatic — real relief for some patients, not a reliable replacement for other therapy. What his tincture sits directly on top of, though, is a well-characterized pharmacologic interaction: both THC and CBD inhibit CYP3A4 and CYP2C9, enzymes centrally involved in warfarin metabolism, and case reports have documented clinically significant INR elevation in patients starting cannabis products alongside stable warfarin therapy. His INR has, by his own report, stayed in range through six months of tincture use — but the product is an unregulated, dispensary-purchased tincture with no verified, consistent THC:CBD ratio from bottle to bottle, which means a stable reading today says less about next month's bottle than it might seem to.
Pain clinic, cannabis disclosure visit
He's already using it, and has been for six months. The National Academies' 2017 review found substantial evidence supporting cannabis and cannabinoids for chronic pain — this isn't a fringe request. Formally supporting and monitoring what he's already doing is safer than leaving it outside our view entirely, where nobody is tracking his INR against it or asking what's actually in the bottle.
I agree bringing it into view is better than ignoring it, but "formally support" undersells a real interaction. THC and CBD both inhibit CYP3A4 and CYP2C9, the enzymes largely responsible for warfarin clearance — that's not a theoretical caution, there are documented case reports of INR spiking after cannabis initiation in patients previously stable on warfarin. His INR being in range today doesn't mean the interaction isn't real; it may just mean this particular batch hasn't pushed it far enough yet.
"He's already doing it safely so far" is exactly the kind of evidence that looks reassuring right up until a different batch or a dose increase changes the picture.
The interaction itself I think we can actively manage — more frequent INR checks would catch a real shift before it becomes dangerous. What monitoring alone can't fix is that this is an unregulated dispensary tincture with no verified THC:CBD ratio from one bottle to the next. A stable INR on this batch tells us almost nothing about the next one he buys, which might have a meaningfully different cannabinoid concentration entirely.
Increasing monitoring frequency answers the pharmacologist's concern about detecting a shift — it doesn't answer the deeper problem that the thing we'd be monitoring against keeps changing without anyone knowing by how much.
Agreed: his cannabis use formally acknowledged and brought into the chart, INR monitoring increased to every one to two weeks initially, and a direct recommendation that he switch to a single, lab-verified cannabinoid product rather than rotating dispensary purchases, so future INR readings can actually be interpreted against a known quantity.
Not agreed: whether he should have been asked to pause cannabis use entirely until a verified product and a documented stable INR on it were established, rather than continuing use through the transition. The pharmacologist's preference was for a brief pause; the pain medicine specialist argued that asking a patient with real reported relief to stop what's working, even briefly, risks him simply not disclosing the next time. He continued use through the transition, with monitoring tightened rather than use interrupted — a decision the pharmacologist signed onto for this specific patient's disclosure history, not as a general rule for every similar case.